JPRN-UMIN000004345
Completed
未知
Phase II clinical trial of the combination of high-dose toremifene and exemestane for advanced/recurrent breast cancer unresponsive to nonsteroidal aromatase inhibitors - Phase II clinical trial of the combination of high-dose toremifene and exemestane for advanced/recurrent breast cancer unresponsive to nonsteroidal aromatase inhibitors
ConditionsAdvanced/recurrent breast cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Advanced/recurrent breast cancer
- Sponsor
- Kyoto Prefectural University of Medicine
- Enrollment
- 30
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. Patients with active double cancer 2\. Patients with life\-threatening symptoms, extensive organ metastasis (1/3 of the organ), or brain metastasis 3\. Patients with a past history of severe drug hypersensitivity 4\. Pregnant or breastfeeding females 5\. Other patients who were considered by the primary care physician to be inappropriate as subjects of this trial
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Phase 2 trial of first-line combination therapy of cisplatin, pemetrexed and nivolumab in participants with unresectable malignant pleural mesotheliomamalignant pleural mesotheliomaJPRN-UMIN000030892Okayama Rosai Hospital18
Active, not recruiting
Not Applicable
Clinical trial to evaluate the treatment with a drug (lenalidomide) with the usually prescribed chemotherapy in patients diagnosed with diffuse large B-cell lymphoma (sort of blood cancer) which did not respond to previous treatments and who can not receive high-dose chemotherapy.EUCTR2014-001620-29-ESGrupo Español para el Tratamiento y Estudio de los Linfomas (GOTEL)77
Completed
Phase 2
Phase II clinical trial of combination therapy with medium-chain triglycerides and ghrelin in patients with chronic obstructive pulmonary diseaseCOPDJPRN-UMIN000015222ational Hospital Organization Toneyama National Hospital10
Active, not recruiting
Not Applicable
A phase II clinical trial on the combination of dabrafenib and trametinib for BRAF-inhibitor pretreated patients with advanced BRAF V600 mutant melanomaadvanced BRAF V600 mutant melanomaMedDRA version: 16.1Level: PTClassification code 10025671Term: Malignant melanoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10025670Term: Malignant melanoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: HLTClassification code 10027156Term: Skin melanomas (excl ocular)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10066600Term: Melanoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10027480Term: Metastatic malignant melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2013-004966-33-BEZ Brussel
Completed
Phase 2
Phase II clinical study of the combination chemotherapy regimen of topotecan plus oral etoposide for the treatment of recurrent ovarian cancerResistant ovarian cancerJPRN-UMIN000007318Kyorin University, School of Medicine20